CN1245977C - 脂质体抗肿瘤药物及其使用 - Google Patents
脂质体抗肿瘤药物及其使用 Download PDFInfo
- Publication number
- CN1245977C CN1245977C CNB018138187A CN01813818A CN1245977C CN 1245977 C CN1245977 C CN 1245977C CN B018138187 A CNB018138187 A CN B018138187A CN 01813818 A CN01813818 A CN 01813818A CN 1245977 C CN1245977 C CN 1245977C
- Authority
- CN
- China
- Prior art keywords
- liposome
- medicine
- hycamtin
- antitumor drug
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
剂量(mg/M2/每剂) | 周期 | 周期间隔 |
0.15 | 1dx5d | 3周 |
0.5 | 1d | 1周 |
1.5 | 1d | 1周 |
15 | 1d | 3周 |
50 | 1d | 3周 |
制剂 | 剂量(mg/kg) | AUC(h·μg/ml) | Cmax(μg/ml) | Cl(ml/h) | α1/2(h) | β1/2(h) |
游离 | 1 | 1.97 | 0.75 | 13.9 | 0.14 | 11.8 |
5 | 2.77 | 2.17 | 49.6 | 0.26 | 11.4 | |
TCS | 1 | 65.7 | 16.3 | 0.417 | 2.79 | |
5 | 453 | 51.0 | 0.302 | 6.16 |
处理方法 | 注射后天数 | WBC(×109/L) | 中性粒细胞(×109/L) | 淋巴细胞(×109/L) | 单核细胞(×109/L) | 嗜酸粒细胞(×109/L) | 嗜碱粒细胞(×109/L) | RBC(×1012/L) | Hb(g/L) | Hb(L/L) | PLT(×109/L) |
对照游离TCS空泡囊 | 321321321 | 6.47±1.626.70±1.955.16±1.182.82±1.052.54±1.434.68±1.135.05±0.64 | 0.937±0.2010.520±0.2000.480±0.1220.048±0.0180.282±0.1670.598±0.2380.898±0.575 | 5.23±1.455.90±1.704.33±0.932.63±0.872.06±1.363.66±0.933.78±0.88 | 0.180±0.0420.177±0.0720.247±0.1800.109±0.1260.133±0.1420.248±0.1680.263±0.163 | 0.059±0.0390.031±0.0210.034±0.160.001±0.0010.019±0.0110.081±0.0440.038±0.036 | 0.056±0.0530.057±0.0400.088±0.0710.034±0.0290.064±0.0600.064±0.0550.072±0.057 | 8.67±0.938.47±0.399.81±0.378.93±0.769.41±0.837.77±0.309.36±0.67 | 142±12136±05154±04141±10154±12130±05152±08 | 0.438±0.0450.444±0.0120.493±0.0140.463±0.0330.486±0.0350.416±0.0140.483±0.033 | 717±317879±145907±059564±0981009±161863±1431366±144 |
处理 | BUN(mmol/L) | 肌酐(μmol/L) | TP(g/L) | 白蛋白(g/L) | 球蛋白(g/L) | 白蛋白/球蛋白比例 | 胆红素(μmol/L) | Alk Phos(IU/L) | ALT(IU/L) | AST(IU/L) | CPK(IU/L) |
对照游离TCS空泡囊 | 11.3±3.09.4±3.210.0±3.9ND | 83±682±1896±2868±13 | 46.7±2.148.0±2.155.8±11.849.3±1.2 | 31.3±1.532.8±1.328.8±2.533.0±1.7 | 15.3±1.215.2±1.127.0±10.116.3±0.6 | 2.07±0.152.16±0.151.18±0.332.00±0.17 | 4.7±0.63.8±0.82.5±0.64.3±0.6 | 86±1267±3573±2170±10 | 27±3113±2323±1717±15 | 59±2255±1077±2953±6 | 87±10756±38155±5456±26 |
肿瘤模型 | 接种途径 | 用量方案 | TIFree | TITCS | TITCS/TIFree |
L1210(鼠白血病)CT-26(鼠结肠)MX-1(人类乳房)LX-1(人类肺) | 静脉内脾内皮下皮下 | 单剂量单剂量单剂量q3dx4qTdx3单剂量q7dx3 | 1.3(2.0)b1.0(1.5)b1.4(2.1)b152.01.3(2.0)b4.0 | 205.02550c15.0c13.318.8 | 15.4(10)b5(3.3)b17.9(11.9)b3.37.510.2(6.7)b4.7 |
模型 | 剂量 | %T/Ca | 抗肿瘤活性 | LCKd | TFe | 毒性 | |||
T-Cb | %ILSc | DRDf | MWLg | ||||||
L1210(静脉内)NCTEF-005CT-26(脾内)NCTEF-005MX-1(皮下)NCTEF-004LX-1(皮下)NCTEF-003 | 游离游离游离游离游离TCSTCSTCSTCSTCS游离游离游离TCSTCSTCS游离游离游离TCSTCSTCS游离游离游离TCSTCSTCS | 510203040151020305104025105104025105103051030 | 7866248-49-6267554313118 | 0.21.44.27.410.214.21.41.92.97.98.79.9 | 112233445544********31235854****01335657483007302222 | 0.020.120.350.620.851.190.130.180.270.740.820.93 | 0/80/80/80/80/80/88/88/87/73/30/80/81/80/88/87/80/60/60/60/60/61/60/60/60/60/60/60/6 | 0/80/80/80/80/80/80/80/81/85/80/80/80/80/80/80/80/60/60/60/60/60/60/60/60/60/60/64/6 | +h+++++++-9.7-14.8-23.4++-0.4+-6.8-19.1++++-0.4-18.3++-1.3-1.7-15.6-29.0 |
模型 | 剂量 | %T/Ca | 抗肿瘤活性 | LCKd | TFe | 毒性 | |||
T-Cb | %ILSc | DRDf | MWLg | ||||||
MX-1(q3dx4)NCTEF-006MX-1(q7dx3)NCTEF-009LX-1(q7dx3)NCTEF-007LX-1(q7dx3)NCTEF-011 | 游离游离游离TCSTCSTCSTCS游离游离TCSTCS游离游离TCSTCSTCS游离游离TCSTCS | 1.252.5100.51.252.5551051010301.252.5510307.50.75 | 553027-15-100-100-1005861-100-100405163-55289NDi27 | 2.05.02.523.5******1.82.0**NDi2.020.910.823.230.24.425NDi11.2 | 205552157******27NDi**NDi215854791004172NDi50 | 0.170.420.211.960.150.141.530.791.702.22 | 0/60/61/61/66/66/66/60/60/66/66/60/60/60/60/60/60/60/60/60/6 | 0/60/60/60/60/60/60/60/60/60/66/60/60/60/60/60/60/62/66/60/6 | +h++-0.3-1.0-11.5-20.0+-0.8-7.6-29.0-6.2-8.8-7.7-7.3-10.5-3.6-16.4>-30-1.3 |
Claims (12)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21555600P | 2000-06-30 | 2000-06-30 | |
US60/215,556 | 2000-06-30 | ||
US26461601P | 2001-01-26 | 2001-01-26 | |
US60/264,616 | 2001-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1446079A CN1446079A (zh) | 2003-10-01 |
CN1245977C true CN1245977C (zh) | 2006-03-22 |
Family
ID=26910152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018138187A Expired - Lifetime CN1245977C (zh) | 2000-06-30 | 2001-06-29 | 脂质体抗肿瘤药物及其使用 |
Country Status (12)
Country | Link |
---|---|
US (7) | US7060828B2 (zh) |
EP (2) | EP1299084B1 (zh) |
JP (3) | JP2004501955A (zh) |
CN (1) | CN1245977C (zh) |
AT (2) | ATE309786T1 (zh) |
AU (3) | AU2001270385B2 (zh) |
CA (2) | CA2412790C (zh) |
DE (2) | DE60115044T2 (zh) |
ES (1) | ES2253398T3 (zh) |
IL (2) | IL153676A0 (zh) |
MX (1) | MXPA02012817A (zh) |
WO (2) | WO2002002078A2 (zh) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
US7452550B2 (en) * | 2000-06-30 | 2008-11-18 | Hana Biosciences, Inc. | Liposomal antineoplastic drugs and uses thereof |
ES2253398T3 (es) * | 2000-06-30 | 2006-06-01 | Inex Pharmaceuticals Corp. | Camptotecinas liposomales mejoradas y sus usos. |
EP1424889A4 (en) * | 2001-08-20 | 2008-04-02 | Transave Inc | PROCESS FOR TREATING LUNG CANCERS |
CN1681478A (zh) * | 2002-08-02 | 2005-10-12 | 川塞夫有限公司 | 铂聚集体及其制备方法 |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
JP2006508126A (ja) * | 2002-11-06 | 2006-03-09 | アザヤ セラピューティクス インコーポレイティッド | 薬学的製剤のタンパク質安定化されたリポソーム製剤 |
US20060222694A1 (en) * | 2003-06-27 | 2006-10-05 | Oh Choon K | Stabilized topotecan liposomal composition and methods |
ES2329374T3 (es) * | 2003-11-14 | 2009-11-25 | Het Nederlands Kanker Instituut (The Netherlands Cancer Institute) | Formulaciones farmaceuticas que utilizan esfingolipidos de cadena corta y usos de las mismas. |
WO2005072776A2 (en) * | 2004-01-30 | 2005-08-11 | Instytut Farmaceutyczny | Liposomal formulations of the antineoplastic agents |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
WO2005089448A2 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
CN107811971B (zh) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
US7811602B2 (en) * | 2004-05-17 | 2010-10-12 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
JP2008500397A (ja) * | 2004-05-21 | 2008-01-10 | トランセイブ, インク. | 肺疾患及び前肺疾患状態の治療 |
ES2594621T3 (es) * | 2004-06-01 | 2016-12-21 | Kabushiki Kaisha Yakult Honsha | Preparación de irinotecán |
WO2006014035A1 (en) * | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
US8349360B2 (en) * | 2004-10-06 | 2013-01-08 | Bc Cancer Agency | Liposomes with improved drug retention for treatment of cancer |
WO2006052767A2 (en) * | 2004-11-05 | 2006-05-18 | Inex Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
JP5735724B2 (ja) * | 2004-11-08 | 2015-06-17 | インスメッド, インコーポレイテッド | 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 |
CN100348194C (zh) * | 2005-07-26 | 2007-11-14 | 康辰医药发展有限公司 | 盐酸洛拉曲克的脂质体制剂及其制备方法 |
CN100375621C (zh) * | 2005-11-04 | 2008-03-19 | 唐星 | 长春瑞滨脂质微球注射液及其制备方法 |
US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US9107824B2 (en) * | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
FR2895258B1 (fr) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
EP2023949A4 (en) * | 2006-04-26 | 2009-08-26 | Univ California | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION |
WO2008070009A2 (en) * | 2006-12-01 | 2008-06-12 | Alza Corporation | Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
US20100093873A1 (en) * | 2008-10-02 | 2010-04-15 | Goldfischer Sidney L | Methods of improving therapy of perfluorocarbons (PFC) |
WO2010058840A1 (ja) * | 2008-11-20 | 2010-05-27 | テルモ株式会社 | リポソームからの薬物放出手段および放出性評価法 |
WO2011085815A1 (en) | 2010-01-14 | 2011-07-21 | Brainlab Ag | Controlling a surgical navigation system |
US9422303B2 (en) | 2010-10-29 | 2016-08-23 | Health Research, Inc. | Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy |
PL226015B1 (pl) | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna |
EP2714011B1 (en) * | 2011-06-03 | 2018-01-31 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
US10349884B2 (en) * | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
US10449193B2 (en) * | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
WO2014039533A2 (en) | 2012-09-04 | 2014-03-13 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
MX2015005992A (es) | 2012-11-20 | 2016-03-07 | Spectrum Pharmaceuticals Inc | Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico. |
SG11201509436TA (en) * | 2013-05-30 | 2015-12-30 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
CA2933204C (en) | 2013-12-18 | 2020-04-28 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
AU2015269699B2 (en) | 2014-06-03 | 2020-08-13 | Avanti Polar Lipids, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies |
LT3229776T (lt) * | 2014-11-25 | 2023-08-25 | Curadigm Sas | Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
ES2848118T3 (es) | 2015-08-20 | 2021-08-05 | Ipsen Biopharm Ltd | Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer |
TWI778942B (zh) | 2015-08-21 | 2022-10-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
CA2940470C (en) * | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
RU2732567C2 (ru) | 2015-10-16 | 2020-09-21 | Ипсен Биофарм Лтд. | Стабилизированные фармацевтические композиции камптотецина |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
CA3038813C (en) | 2016-04-27 | 2021-08-24 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
EP3506909B1 (en) | 2016-09-02 | 2022-06-29 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
BR112019007844A2 (pt) | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
EP3603620A4 (en) | 2017-03-31 | 2020-03-25 | FUJIFILM Corporation | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION |
WO2019160732A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
TWI737974B (zh) * | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
US20210361575A1 (en) * | 2018-04-11 | 2021-11-25 | New Mexico Tech University Research Park Corporation | Lipid prodrugs for use in drug delivery |
JP7036919B2 (ja) | 2018-06-20 | 2022-03-15 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
JP7057434B2 (ja) | 2018-10-01 | 2022-04-19 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
MX2021011928A (es) | 2019-03-29 | 2022-01-04 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. |
EP3963072A1 (en) | 2019-05-03 | 2022-03-09 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
CN115461042A (zh) * | 2019-12-20 | 2022-12-09 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
AU2021207504A1 (en) | 2020-01-15 | 2022-08-04 | Dicerna Pharmaceuticals, Inc. | 4'-O-methylene phosphonate nucleic acids and analogues thereof |
KR20230061389A (ko) | 2020-08-04 | 2023-05-08 | 다이서나 파마수이티컬, 인크. | 올리고뉴클레오티드의 전신 전달 |
JPWO2022250013A1 (zh) | 2021-05-24 | 2022-12-01 | ||
WO2022250015A1 (ja) | 2021-05-24 | 2022-12-01 | 富士フイルム株式会社 | 処置剤 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
WO1987004592A1 (en) * | 1986-02-10 | 1987-08-13 | Liposome Technology, Inc. | Controlled-release liposome delivery system |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5552154A (en) * | 1989-11-06 | 1996-09-03 | The Stehlin Foundation For Cancer Research | Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof |
US5552156A (en) * | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
EP0721328A4 (en) * | 1993-09-27 | 1997-09-17 | Smithkline Beecham Corp | CAMPTOTHECIN FORMULATIONS |
US6855331B2 (en) * | 1994-05-16 | 2005-02-15 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
NZ295546A (en) * | 1994-10-05 | 1999-01-28 | Glaxo Wellcome Inc | Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer |
US5972379A (en) | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
DE69634084T2 (de) * | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
WO1998017256A1 (en) | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
CA2303366A1 (en) * | 1997-09-16 | 1999-03-25 | Nexstar Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
KR100679906B1 (ko) * | 1998-09-16 | 2007-02-07 | 알자 코포레이션 | 리포솜-엔트랩된 토포이소머라제 억제제 |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6191119B1 (en) * | 1999-10-15 | 2001-02-20 | Supergen, Inc. | Combination therapy including 9-nitro-20(S)-camptothecin |
ES2253398T3 (es) * | 2000-06-30 | 2006-06-01 | Inex Pharmaceuticals Corp. | Camptotecinas liposomales mejoradas y sus usos. |
BR0114713A (pt) * | 2000-10-16 | 2004-01-13 | Neopharm Inc | Formulação lipossÈmica de mitoxantrona |
US6825206B1 (en) * | 2000-11-16 | 2004-11-30 | Research Triangle Institute | Camptothecin compounds with a thioether group |
US6627614B1 (en) * | 2002-06-05 | 2003-09-30 | Super Gen, Inc. | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline |
-
2001
- 2001-06-29 ES ES01949169T patent/ES2253398T3/es not_active Expired - Lifetime
- 2001-06-29 JP JP2002506699A patent/JP2004501955A/ja not_active Withdrawn
- 2001-06-29 CA CA2412790A patent/CA2412790C/en not_active Expired - Lifetime
- 2001-06-29 DE DE60115044T patent/DE60115044T2/de not_active Expired - Lifetime
- 2001-06-29 WO PCT/CA2001/000981 patent/WO2002002078A2/en active IP Right Grant
- 2001-06-29 AT AT01949141T patent/ATE309786T1/de not_active IP Right Cessation
- 2001-06-29 EP EP01949141A patent/EP1299084B1/en not_active Expired - Lifetime
- 2001-06-29 AU AU2001270385A patent/AU2001270385B2/en not_active Expired
- 2001-06-29 WO PCT/CA2001/000925 patent/WO2002002077A2/en active IP Right Grant
- 2001-06-29 EP EP01949169A patent/EP1299085B1/en not_active Expired - Lifetime
- 2001-06-29 CA CA2412795A patent/CA2412795C/en not_active Expired - Lifetime
- 2001-06-29 US US09/896,811 patent/US7060828B2/en not_active Expired - Lifetime
- 2001-06-29 AU AU7038501A patent/AU7038501A/xx active Pending
- 2001-06-29 AU AU2001270413A patent/AU2001270413A1/en not_active Abandoned
- 2001-06-29 MX MXPA02012817A patent/MXPA02012817A/es active IP Right Grant
- 2001-06-29 US US09/896,812 patent/US7244448B2/en not_active Expired - Lifetime
- 2001-06-29 DE DE60115045T patent/DE60115045T2/de not_active Expired - Lifetime
- 2001-06-29 CN CNB018138187A patent/CN1245977C/zh not_active Expired - Lifetime
- 2001-06-29 IL IL15367601A patent/IL153676A0/xx active IP Right Grant
- 2001-06-29 AT AT01949169T patent/ATE309787T1/de not_active IP Right Cessation
-
2002
- 2002-12-26 IL IL153676A patent/IL153676A/en unknown
-
2004
- 2004-02-27 US US10/788,649 patent/US20040170678A1/en not_active Abandoned
-
2005
- 2005-12-06 US US11/294,826 patent/US20060093662A1/en not_active Abandoned
-
2006
- 2006-05-08 US US11/429,911 patent/US20060269594A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/963,888 patent/US20110086826A1/en not_active Abandoned
-
2012
- 2012-02-09 JP JP2012025785A patent/JP2012092148A/ja active Pending
- 2012-06-28 US US13/536,325 patent/US20130136787A1/en not_active Abandoned
-
2014
- 2014-02-17 JP JP2014027576A patent/JP2014088444A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245977C (zh) | 脂质体抗肿瘤药物及其使用 | |
CN1205923C (zh) | 脂质体包封的拓扑异构酶抑制剂 | |
EP2246056B1 (en) | Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation | |
AU2001270385A1 (en) | Liposomal antineoplastic drugs and uses thereof | |
US7452550B2 (en) | Liposomal antineoplastic drugs and uses thereof | |
CN105050409B (zh) | 使用大豆磷脂酰丝氨酸制备的脂质卷 | |
CN1469735A (zh) | 米托蒽醌的脂质体制剂 | |
Perez et al. | Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes | |
CN1212122C (zh) | 三七总皂苷脂质体及其制剂 | |
CN110898231A (zh) | 一种功能化拉洛他赛脂质体及其制备方法与应用 | |
CN1277024A (zh) | 阳离子脂质体和多脱氧核糖核苷酸的复合物作为药剂的用途 | |
WO2023230711A1 (en) | Lipid nanoparticle for the delivery of rna | |
JP2012508749A (ja) | 多発性骨髄腫治療のためのベンダムスチン、ドキソルビシンおよびボルテゾミブの併用 | |
CN1756534A (zh) | 用于减少脂质体诱导的补体激活的脂质体组合物 | |
US20150306035A1 (en) | Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TAIKEMILA MEDICINE CO., LTD. Free format text: FORMER OWNER: INEX PHARAMCEUTICALS CORP. Effective date: 20080425 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080425 Address after: British Columbia Canada Patentee after: Tektronix Mira pharmaceuticals Limited by Share Ltd Address before: British Columbia Canada Patentee before: Inex Pharamceuticals Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: TYLOON ACOLOGY CO., LTD. Free format text: FORMER OWNER: TECHMILA MEDICINE1 CO., LTD. Effective date: 20120301 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120301 Address after: American California Patentee after: Study of Limited by Share Ltd Tyrone treatment Address before: British Columbia Canada Patentee before: Tektronix Mira pharmaceuticals Limited by Share Ltd |
|
CX01 | Expiry of patent term |
Granted publication date: 20060322 |
|
CX01 | Expiry of patent term |